Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products.
Liverpool, GB
Size (employees)
2 (est)
Evgen Pharma was founded in 2007 and is headquartered in Liverpool, GB
Report incorrect company information

Key People/Management at Evgen Pharma

Stephen Franklin

Stephen Franklin

Chief Executive Officer
Alan Barge

Alan Barge

Non-Executive Director
Susan Foden

Susan Foden

Non-Executive Director
Marc d’Abbadie

Marc d’Abbadie

Non-Executive Director
Barry Clare

Barry Clare

Non-Executive Chairman

Evgen Pharma Office Locations

Evgen Pharma has offices in Liverpool and London
Liverpool, GB (HQ)
Liverpool Science Park Innovation Centre 2 146 Brownlow Hill
London, GB
107 Cheapside
Show all (2)
Report incorrect company information

Evgen Pharma Financials and Metrics

Evgen Pharma Financials


Net income (FY, 2017)

(3.1 m)

Market capitalization (31-Oct-2017)

12.6 m

Closing share price (31-Oct-2017)


Cash (31-Mar-2017)

3.9 m
Evgen Pharma's current market capitalization is £12.6 m.
GBPFY, 2015FY, 2016FY, 2017


(1.2 m)


(1.2 m)

Pre tax profit

(2.3 m)(3.2 m)(3.6 m)

Income tax expense

30 k85 k576 k
GBPFY, 2015FY, 2016FY, 2017


163 k7.1 m3.9 m

Accounts Receivable

6 k3 k

Current Assets

310 k7.3 m4.6 m


1 k6 k11 k
GBPFY, 2015FY, 2016FY, 2017

Net Income

(2.3 m)(3.1 m)(3.1 m)

Cash From Operating Activities

(900 k)(1.6 m)(3.2 m)

Cash From Financing Activities

750 k8.6 m

Net Change in Cash

(151 k)5 m(1.3 m)
GBPY, 2017

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information